Registration for International Lung Cancer Summit 2026 is now open. Join co-chairs @peters_solange and @Alfdoc2 on the ILCS to discuss how the latest trial data impacts everyday clinical decisions. This is your opportunity to connect with colleagues and debate real-world treatment strategies for advanced NSCLC and SCLC. 🗓️ Friday, November 13ᵗʰ, 2026 📍 Lausanne, Switzerland & Live Online Secure your spot here ⬇️ lungsummit.org/#ILCS

Super excited to host the ALKconnect event in Athens🇬🇷 with amazing KOLs from around the globe for a two-days immersive workshop on ALK positive #NSCLC @bensolomon1 @JessicaJLinMD @ElinardouHelena @peters_solange @davidplanchard @PrelajArsela @ALKPositiveinc @ALKpositiveINT @alk_fusion @HenryDunantGR

The hallmarks of cancer as the framework a student needs before a case: from the original set articulated by Douglas Hanahan and Robert Weinberg, uncontrolled proliferation through to angiogenesis and metastasis, to the later additions of immune evasion and, more recently, plasticity. A hallmark is a trait an incipient cancer cell has to acquire to become invasive. The framework is the one @FSkoulidis, @UTMDAnderson taught in Gruyères.

@g_mountzios, at the @etop_ibcsg workshop on T-cell engagers, on the gap between an approved drug and a department ready to give it. The statement is specific: guidance posted where staff stand, the ICE score in routine use, tocilizumab prepared before each cycle. The position statement from that workshop is out now: doi.org/10.1016/j.ctrv.2026.…

A summer school that should, in its chair's words, “allow the students to reflect and to think and to start to have a scientific way of thinking to be brought in their daily practice”, whether or not those students become oncologists. The reason for teaching it through oncology is that the field shows science translating into survival. We put that to @MdCurioni at her own summer school in Gruyères.

Drug development is measured in survival and response. What a patient and a physician weigh in the room is the likelihood of benefit against the risk of side effects, which on her account is what truly personalises a decision and what decides whether a healthcare system takes an approach up at all. It is still seen as a secondary question when, in her words, it is a core one. @DrJNaidoo from @CancerCentreIre spoke to us at the summer school in Gruyères.

NGS and liquid biopsy are already a reality in clinical practice; turning what they find into a treatment decision is the hard part. He calls the volume of new findings “a genomic tsunami”, and what he asks for is structural: a molecular tumour board, a level of evidence attached to every decision, and the technology accessible to everyone rather than at a few centres. @ChristianRolfo, @OSUCCC_James, interviewed at the Swiss Oncology Summer School.

@GautschiOliver, in a recent interview on the changing role of antibody drug conjugates in NSCLC, on what has shifted over the last two years. Response rates matter, but the more meaningful signal, he argues, is the overall survival benefit now emerging alongside quality of life data. ADCs are not pure biological molecules; the attached payload behaves like chemotherapy and carries its own toxicity signature. His view on the near future: ADCs will move into front line therapy, and that creates a new problem. The more we combine up front, the harder it becomes to keep meaningful options for the second and third line. Approvals are still catching up with a pipeline that has largely read out, with expanded access programs bridging the gap. Watch the full interview to hear where Prof. Gautschi sees the sequencing questions landing next ➡️ lungsummit.org/latest/

We will need more oncologists in future, and the two reasons @MdCurioni , of the Cantonal Hospital Fribourg (HFR), gives are a growing population and a growing number of cancer survivors. The Swiss Oncology Summer School, an idea she first had a long time ago, puts the science first and the clinical cases second, so that a student grasps how a disease is understood before meeting the treatment that follows from it. When she was a medical student, in her words, the understanding of oncology was “this small” against what is available today. We met her at the recent school in Gruyères and were impressed by her team's dedication for future generations in medicine.

Five readouts in one Seoul afternoon, and the two EGFR exon 20 trials pulled opposite ways. 📈 ADAURA: adjuvant osimertinib, resected stage IB-IIIA EGFR-mutant NSCLC, 8-yr OS 79% vs 64%, HR 0.52 (exploratory landmark) ❌ PAPILLON: 1L amivantamab-chemotherapy, EGFR exon 20 insertions, mOS 34.3 vs 27.9 mo, HR 0.87, p=0.307 (76% crossed over) ✅ REZILIENT 3: zipalertinib + chemo, 1L EGFR exon 20 insertions, mPFS 14.5 vs 8.5 mo, HR 0.50 (more Gr ≥3) 📊 ARROS-1: zidesamtinib, TKI-naive ROS1-positive NSCLC, ORR 93% (all 10 with measurable brain disease responded) ⚠️ DESTINY-Lung04: 1L T-DXd vs pembrolizumab-chemo, HER2-mutant NSCLC, mPFS 14.3 vs 8.3 mo, HR 0.63 (interim OS HR 1.15) Read up on these trials presented at lungsummit.org/articles/wclc…

@GautschiOliver, in a recent interview on molecular profiling in NSCLC, on why comprehensive testing belongs in routine diagnostics rather than in the discretion of individual clinicians. There are roughly ten druggable driver alterations today and the list keeps growing; where public health insurance covers the tests, comprehensive testing at diagnosis should be the default. The interpretation, he cautions, is the harder part. Multiple alterations on one report demand a molecular tumor board to identify which is truly actionable, and to steer clinicians away from incidental findings. Re-biopsy samples are the highest yield discussions in these boards, and lung cancer occasionally shows hereditary syndromes that need genetic counselling for the next generation. Watch the full interview to hear how Prof. Gautschi structures diagnostics around this complexity ➡️ lungsummit.org/latest/

Ivonescimab extended OS against pembrolizumab in 1L PD-L1-positive NSCLC, with no chemotherapy in either arm. Every patient was enrolled in China. 🔬 HARMONi-2: ivonescimab vs pembrolizumab, 1L PD-L1-positive NSCLC, China 📊 mPFS 11.1 vs 5.8 mo, HR 0.51 (p<0.0001, previously reported) 📊 mOS 30.75 vs 22.57 mo, HR 0.73, p=0.009 (second interim) ⚠️ serious treatment-related events 29.9% vs 21.6% ✅ Primary endpoint met Read more at lungsummit.org/articles/wclc…

Zipalertinib plus chemotherapy adds six months of mPFS in 1L EGFR exon 20 insertion NSCLC. Gr ≥3 treatment-related events double, and three patients died of treatment. Presented by @danieltanmd during WCLC 2026. 🔬 REZILIENT 3: zipalertinib + platinum-pemetrexed vs chemotherapy, 1L EGFR exon 20 insertions 📊 mPFS by BICR 14.5 vs 8.5 mo, HR 0.50, p=0.00015 (boundary 0.0196) 📊 ORR 65.0% vs 40.3% (DoR 14.2 vs 9.9 mo) ⚠️ Gr ≥3 treatment-related events 80.7% vs 40.4% ✅ Primary endpoint met Learn more about this trial and its results at: lungsummit.org/articles/wclc…

Day 4 in Seoul: a pathology grade that picks out who benefits from adjuvant chemotherapy, a BRAF subgroup with worse survival, and a screening van in Northeast Brazil. 📊 PRESERVE-003: gotistobart vs docetaxel, squamous NSCLC after PD-(L)1-platinum, mOS 18.5 vs 10.0 mo, HR 0.56 (Stage 1, nominal p) 📊 BRAF class III: 1L immunotherapy, non-V600 BRAF-only NSCLC, mOS 12.7 vs 20.5 mo, HR 1.47 (vs class II) 📊 IASLC budding grade: 585 resected lung SqCC, high grade 11.1% (adjuvant chemo DFS HR 0.52, p=0.071, not significant) 📊 Early cranial SRT: osimertinib, EGFR-mutant NSCLC, limited brain mets, intracranial mPFS 48.5 vs 20.0 mo (not randomised; propensity-matched) 📊 BRELT3: mobile low-dose CT, 2,018 screened, Northeast Brazil, cancers found 19 (0.94%; 44.3% recruited by health workers) Get our round-up from WCLC at lungsummit.org/articles/wclc…

First-line T-DXd nearly doubled mPFS against pembrolizumab plus chemotherapy in HER2-mutant NSCLC. Interim OS points the other way, and one in five had drug-related lung disease. 🔬 DESTINY-Lung04: 1L T-DXd vs pembrolizumab-chemotherapy, HER2-mutant NSCLC 📊 mPFS by BICR 14.3 vs 8.3 mo, HR 0.63 (p<0.0001) 📊 mOS 29.3 vs 33.1 mo, HR 1.15 (first interim, no formal test) ⚠️ drug-related ILD or pneumonitis 20.8% vs 2.3% ⚠️ PFS met, interim OS HR 1.15 Data presented by @JuliaRotow during WCLC 2026. Learn more at: lungsummit.org/articles/wclc…

All ten TKI-naive ARROS-1 patients evaluable for brain response responded intracranially, seven of them completely. 🔬 ARROS-1: zidesamtinib 100 mg once daily, single-arm, TKI-naive ROS1-positive NSCLC 📊 ORR 94% 📊 intracranial ORR 100% (10 of 10, 7 complete) ⚠️ treatment-related peripheral edema 34% ⚠️ Single-arm registrational cohort, no formal test More about this trial and its results here: lungsummit.org/articles/wclc…

Eight years after randomisation in ADAURA, three of them on treatment, the adjuvant osimertinib and placebo curves are still apart. 🔬 ADAURA: adjuvant osimertinib vs placebo, resected stage IB-IIIA EGFR-mutant NSCLC 📊 8-yr OS, stage II-IIIA 74% vs 58%, HR 0.53 (post hoc landmark) 📊 8-yr OS, stage IB-IIIA 79% vs 64%, HR 0.52 ⚠️ Primary endpoint met in 2020; this landmark is exploratory lungsummit.org/articles/wclc…

Three-quarters of the PAPILLON patients who progressed on chemotherapy went on to amivantamab. Trial and results were presented by @chulkimMD from @MedStarGUH. 🔬 PAPILLON: 1L amivantamab-chemotherapy vs chemotherapy, EGFR exon 20 insertions 📊 mPFS 11.4 vs 6.7 mo, HR 0.40 (primary analysis) 📊 mOS, final 34.3 vs 27.9 mo, HR 0.87, p=0.307 📊 chemotherapy mOS adjusted for crossover 22.1 mo, HR 0.57 (IPCW, nominal) ⚠️ PFS met at the primary analysis, final OS not significant Learn more about this study and its results at: lungsummit.org/articles/wclc…

Thanks @HHorinouchi! 5 years of work, a PhD and some white hair later, delighted to share our work in @JTOonline. We show multi-omic profiling enables molecular risk stratification of stage I-III EGFRm NSCLC to inform adjuvant TKI benefit. Grateful to my mentors and co-authors 🙏🏻